Average UK trade prices of olmesartan as much as trebled across multiple presentations in the second month of 2021. However, this was not the only triple-digit price rise seen during February, WaveData reveals.

Hyloris is on a roll with licensing deals for its Maxigesic IV non-opioid pain treatment, with an extension of its existing agreement with Pharma Bavaria to cover South American territories coming hot on the heels of recent developments in the US and Europe.

Australia’s government has agreed to extend a successful biosimilar education initiative led by the local GBMA industry association.